Related Experiment Video
Updated: Jun 5, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet and anticoagulant therapy during coronary thrombolysis
D J Fitzgerald1, G A Fitzgerald
1Divisions of Clinical Pharmacology and Cardiology, Vanderbilt University, Nashville, TN 37232, USA.
Insights
Adding antiplatelet and anticoagulant agents to plasminogen activators may improve outcomes for acute myocardial infarction patients. This combination therapy could enhance reperfusion and reduce reocclusion rates, improving treatment effectiveness.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Plasminogen activators are crucial for acute myocardial infarction (AMI) reperfusion, reducing mortality by restoring blood flow to viable myocardium.
- Key factors influencing thrombolytic therapy success include coronary artery patency, reperfusion timing, and reocclusion rates.
Purpose of the Study:
- To evaluate the potential benefits of combining antiplatelet and anticoagulant agents with plasminogen activators in AMI treatment.
- To address limitations of current thrombolytic therapy, such as incomplete reperfusion and reocclusion.
Main Methods:
- Review of experimental and clinical evidence on thrombolytic therapy in AMI.
- Analysis of the role of platelet activation and thrombosis in limiting thrombolytic efficacy.
Main Results:
- Current thrombolytic agents achieve coronary patency in only 50%-70% of AMI patients, with delayed reperfusion.
- Incomplete clot lysis and residual stenosis limit reperfusion flow, while reocclusion occurs in 15%-25% of cases.
- Ongoing platelet activation and thrombosis contribute significantly to suboptimal outcomes.
Conclusions:
- Combining antiplatelet and anticoagulant agents with plasminogen activators is a rational strategy to enhance thrombolytic therapy.
- This adjunctive therapy holds promise for improving myocardial salvage and reducing adverse events in AMI patients.
Abstract:
Plasminogen activators reduce mortality in patients with acute myocardial infarction primarily by inducing reperfusion at a time when the myocardium is still viable. Consequently, important determinants of the clinical response to thrombolytic therapy include the patency rate, the timing of reperfusion, and the frequency of coronary reocclusion. With present thrombolytic agents, coronary patency is not achieved in 30%-50% of patients and reperfusion is often delayed for more than 60 min after initiating thrombolytic therapy. Even in those that achieve patency, reperfusion flow, an important determinant of myocardial salvage, may be limited by incomplete clot lysis and residual coronary stenosis. Finally, reocclusion has been reported in 15%-25% of patients and has serious clinical consequences. Experimental and clinical evidence suggests that many of these problems reflect ongoing platelet activation and thrombosis. Thus, there is a rational basis to assume that the clinical benefit of thrombolytic therapy will be enhanced by the addition of antiplatelet and anticoagulant agents.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...